Rimonabant  	Rimonabant  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
overweight  	overweight  	 NN	O
and  	and  	 CC	O
obese  	obese  	 JJ	O
people  	people  	 NNS	O
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	O
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
rimonabant  	rimonabant  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
obese  	obese  	 NN	O
or  	or  	 CC	O
overweight  	overweight  	 JJ	O
patients  	patients  	 NNS	O
based  	based  	 VBN	O
upon  	upon  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Centre  	Centre  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	B-NP
technology  	technology  	 NN	I-NP
appraisal  	appraisal  	 NN	I-NP
( 	( 	 -LRB-	O
STA 	STA 	 NNP	B-NP
)  	)  	 -RRB-	O
process 	process 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
submission 	submission 	 NN	O
's  	's  	 POS	O
main  	main  	 JJ	O
evidence  	evidence  	 NN	O
came  	came  	 VBD	O
from  	from  	 IN	O
four  	four  	 CD	O
randomised  	randomised  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trials 	trials 	 NNS	I-NP
.  	.  	 .	O
Rimonabant  	Rimonabant  	 NNP	B-NP
resulted  	resulted  	 VBD	O
in  	in  	 IN	O
a  	a  	 DT	O
significantly  	significantly  	 RB	O
greater  	greater  	 JJR	O
benefit  	benefit  	 NN	O
than  	than  	 IN	O
placebo  	placebo  	 NN	O
for  	for  	 IN	O
all  	all  	 DT	O
primary  	primary  	 JJ	B-NP
weight  	weight  	 NN	I-NP
loss  	loss  	 NN	I-NP
outcomes 	outcomes 	 NNS	I-NP
.  	.  	 .	O
At  	At  	 IN	O
1  	1  	 CD	O
year 	year 	 NN	O
,  	,  	 ,	O
rimonabant  	rimonabant  	 NN	B-NP
had  	had  	 VBD	O
a  	a  	 DT	O
statistically  	statistically  	 JJ	O
significant  	significant  	 JJ	O
beneficial  	beneficial  	 JJ	O
effect  	effect  	 NN	O
on  	on  	 IN	O
systolic  	systolic  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure 	pressure 	 NN	I-NP
,  	,  	 ,	O
high-density  	high-density  	 JJ	B-NP
lipoprotein  	lipoprotein  	 JJ	I-NP
cholesterol 	cholesterol 	 NN	I-NP
,  	,  	 ,	O
triglycerides  	triglycerides  	 NN	B-NP
and  	and  	 CC	O
fasting  	fasting  	 JJ	O
plasma  	plasma  	 JJ	B-NP
glucose  	glucose  	 NN	I-NP
in  	in  	 IN	O
diabetics  	diabetics  	 NNS	O
and  	and  	 CC	O
non-diabetics 	non-diabetics 	 JJ	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
glycosylated  	glycosylated  	 JJ	B-NP
haemoglobin  	haemoglobin  	 NN	I-NP
in  	in  	 IN	O
diabetics 	diabetics 	 NNS	O
.  	.  	 .	O
Improvements  	Improvements  	 NNS	B-NP
were  	were  	 VBD	O
maintained  	maintained  	 VBN	O
over  	over  	 IN	O
2  	2  	 CD	O
years  	years  	 NNS	O
with  	with  	 IN	O
rimonabant 	rimonabant 	 NNS	B-NP
;  	;  	 :	O
withdrawal  	withdrawal  	 NN	B-NP
of  	of  	 IN	I-NP
rimonabant  	rimonabant  	 NN	I-NP
at  	at  	 IN	O
1  	1  	 CD	O
year  	year  	 NN	O
resulted  	resulted  	 VBD	O
in  	in  	 IN	O
a  	a  	 DT	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
weight  	weight  	 NN	B-NP
loss  	loss  	 NN	I-NP
until  	until  	 IN	O
there  	there  	 EX	O
was  	was  	 VBD	O
no  	no  	 DT	O
difference  	difference  	 NN	O
from  	from  	 IN	O
placebo  	placebo  	 NN	O
at  	at  	 IN	O
2  	2  	 CD	O
years 	years 	 NNS	O
.  	.  	 .	O
Psychiatric  	Psychiatric  	 JJ	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
were  	were  	 VBD	O
experienced  	experienced  	 VBN	O
by  	by  	 IN	O
26 	26 	 CD	O
%  	%  	 NN	O
and  	and  	 CC	O
14 	14 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
rimonabant  	rimonabant  	 NN	B-NP
and  	and  	 CC	O
placebo  	placebo  	 JJ	O
patients  	patients  	 NNS	O
respectively 	respectively 	 RB	O
;  	;  	 :	O
figures  	figures  	 NNS	O
for  	for  	 IN	O
symptoms  	symptoms  	 NNS	B-NP
of  	of  	 IN	O
depression  	depression  	 NN	O
were  	were  	 VBD	O
9 	9 	 CD	O
%  	%  	 NN	O
and  	and  	 CC	O
5 	5 	 CD	O
%  	%  	 NN	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
Pairwise  	Pairwise  	 JJ	B-NP
comparisons  	comparisons  	 NNS	I-NP
of  	of  	 IN	I-NP
orlistat 	orlistat 	 NN	I-NP
,  	,  	 ,	O
sibutramine  	sibutramine  	 NN	B-NP
and  	and  	 CC	O
rimonabant  	rimonabant  	 NNS	B-NP
showed  	showed  	 VBD	O
beneficial  	beneficial  	 JJ	O
effects  	effects  	 NNS	O
of  	of  	 IN	O
rimonabant  	rimonabant  	 NN	B-NP
over  	over  	 IN	O
orlistat  	orlistat  	 NN	B-NP
and  	and  	 CC	O
sibutramine  	sibutramine  	 NN	B-NP
for  	for  	 IN	I-NP
weight  	weight  	 NN	I-NP
loss  	loss  	 NN	I-NP
outcomes 	outcomes 	 NNS	I-NP
;  	;  	 :	O
however 	however 	 RB	O
,  	,  	 ,	O
response  	response  	 NN	B-NP
hurdles  	hurdles  	 NNS	I-NP
imposed  	imposed  	 VBN	O
on  	on  	 IN	O
orlistat  	orlistat  	 NN	B-NP
or  	or  	 CC	O
sibutramine  	sibutramine  	 NN	B-NP
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
practice  	practice  	 NN	I-NP
may  	may  	 MD	O
not  	not  	 RB	O
have  	have  	 VBP	O
been  	been  	 VBN	O
applied  	applied  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
orlistat  	orlistat  	 NN	B-NP
and  	and  	 CC	O
sibutramine  	sibutramine  	 JJ	B-NP
trials 	trials 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
Markov  	Markov  	 NNP	B-NP
cohort  	cohort  	 FW	I-NP
model  	model  	 FW	I-NP
evaluated  	evaluated  	 FW	I-NP
rimonabant  	rimonabant  	 FW	I-NP
versus  	versus  	 FW	O
orlistat 	orlistat 	 FW	B-NP
,  	,  	 ,	O
sibutramine  	sibutramine  	 NN	B-NP
and  	and  	 CC	O
diet  	diet  	 NN	O
and  	and  	 CC	O
exercise  	exercise  	 VB	O
alone  	alone  	 RB	O
for  	for  	 IN	O
three  	three  	 CD	O
base-case  	base-case  	 JJ	B-NP
populations 	populations 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
incremental  	incremental  	 JJ	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratio  	ratio  	 NN	I-NP
( 	( 	 -LRB-	O
ICER 	ICER 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
rimonabant  	rimonabant  	 JJ	B-NP
varied  	varied  	 NN	I-NP
from  	from  	 IN	O
10,534  	10,534  	 CD	O
pounds  	pounds  	 NNS	O
to  	to  	 TO	O
13,236  	13,236  	 CD	O
pounds  	pounds  	 NNS	O
per  	per  	 IN	O
quality-adjusted  	quality-adjusted  	 JJ	B-NP
life-year  	life-year  	 NN	I-NP
( 	( 	 -LRB-	O
QALY 	QALY 	 NNP	B-NP
)  	)  	 -RRB-	O
versus  	versus  	 CC	O
diet  	diet  	 NN	O
and  	and  	 CC	O
exercise 	exercise 	 NN	O
,  	,  	 ,	O
to  	to  	 TO	O
8977  	8977  	 CD	O
pounds  	pounds  	 NNS	O
to  	to  	 TO	O
12,138  	12,138  	 FW	O
pounds  	pounds  	 FW	O
per  	per  	 FW	O
QALY  	QALY  	 FW	B-NP
versus  	versus  	 FW	O
orlistat 	orlistat 	 FW	B-NP
,  	,  	 ,	O
to  	to  	 TO	O
1463  	1463  	 CD	O
pounds  	pounds  	 NNS	O
to  	to  	 TO	O
3908  	3908  	 CD	O
pounds  	pounds  	 NNS	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
versus  	versus  	 FW	O
sibutramine 	sibutramine 	 FW	B-NP
.  	.  	 .	O
In  	In  	 IN	O
subgroup  	subgroup  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
there  	there  	 EX	O
was  	was  	 VBD	O
a  	a  	 DT	O
wider  	wider  	 JJR	O
variation  	variation  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
ICER  	ICER  	 NNP	B-NP
estimates  	estimates  	 NNS	I-NP
although  	although  	 IN	O
none  	none  	 NN	O
exceeded  	exceeded  	 VBD	O
20,000  	20,000  	 CD	O
pounds  	pounds  	 NNS	O
per  	per  	 IN	O
QALY 	QALY 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
ICER  	ICER  	 NNP	B-NP
of  	of  	 IN	I-NP
rimonabant  	rimonabant  	 NN	I-NP
remained  	remained  	 VBD	O
under  	under  	 IN	O
20,000  	20,000  	 CD	O
pounds  	pounds  	 NNS	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
in  	in  	 IN	O
reanalyses  	reanalyses  	 NN	B-NP
by  	by  	 IN	O
the  	the  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
ERG 	ERG 	 NNP	O
,  	,  	 ,	O
with  	with  	 IN	O
the  	the  	 DT	O
results  	results  	 NNS	O
sensitive  	sensitive  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
source  	source  	 NN	O
of  	of  	 IN	O
health-related  	health-related  	 JJ	B-NP
quality  	quality  	 NN	I-NP
of  	of  	 IN	I-NP
life  	life  	 NN	I-NP
( 	( 	 -LRB-	O
HRQoL 	HRQoL 	 NNP	B-NP
)  	)  	 -RRB-	O
benefits  	benefits  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
model 	model 	 NN	O
.  	.  	 .	O
Four  	Four  	 CD	O
treatment  	treatment  	 NN	B-NP
strategies  	strategies  	 NNS	I-NP
were  	were  	 VBD	O
modelled  	modelled  	 VBN	O
in  	in  	 IN	O
comparisons  	comparisons  	 NNS	O
of  	of  	 IN	O
rimonabant  	rimonabant  	 FW	B-NP
versus  	versus  	 FW	O
diet  	diet  	 FW	O
and  	and  	 CC	O
exercise  	exercise  	 VB	O
alone  	alone  	 RB	O
and  	and  	 CC	O
orlistat  	orlistat  	 NNS	B-NP
and  	and  	 CC	O
sibutramine  	sibutramine  	 NN	B-NP
in  	in  	 IN	O
which  	which  	 WDT	O
rimonabant  	rimonabant  	 NNS	B-NP
was  	was  	 VBD	O
continued  	continued  	 VBN	O
only  	only  	 RB	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
achieving  	achieving  	 VBG	O
5 	5 	 CD	O
%  	%  	 NN	O
weight  	weight  	 NN	B-NP
loss  	loss  	 NN	I-NP
at  	at  	 IN	O
3 	3 	 CD	O
,  	,  	 ,	O
6 	6 	 CD	O
,  	,  	 ,	O
9  	9  	 CD	O
or  	or  	 CC	O
12  	12  	 CD	O
months 	months 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
pairwise  	pairwise  	 JJ	B-NP
comparisons  	comparisons  	 NNS	I-NP
rimonabant  	rimonabant  	 VBP	O
remained  	remained  	 VBN	O
below  	below  	 IN	O
a  	a  	 DT	O
threshold  	threshold  	 NN	O
of  	of  	 IN	O
30,000  	30,000  	 CD	O
pounds  	pounds  	 NNS	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
in  	in  	 IN	O
70 	70 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
comparisons  	comparisons  	 NNS	O
reported 	reported 	 VBD	O
.  	.  	 .	O
The  	The  	 DT	O
results  	results  	 NNS	O
were  	were  	 VBD	O
most  	most  	 RBS	O
sensitive  	sensitive  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
decrement  	decrement  	 NN	B-NP
applied  	applied  	 VBD	O
to  	to  	 TO	O
depression  	depression  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
costs  	costs  	 NNS	O
of  	of  	 IN	O
screening  	screening  	 NN	O
for  	for  	 IN	O
depression 	depression 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
areas  	areas  	 NNS	O
of  	of  	 IN	O
uncertainty  	uncertainty  	 NN	O
remain  	remain  	 VBP	O
in  	in  	 IN	O
relation  	relation  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
rimonabant 	rimonabant 	 NN	I-NP
,  	,  	 ,	O
for  	for  	 IN	O
example  	example  	 NN	B-NP
lack  	lack  	 NN	I-NP
of  	of  	 IN	O
evidence  	evidence  	 NN	O
on  	on  	 IN	O
long-term  	long-term  	 JJ	O
outcomes  	outcomes  	 NNS	O
and  	and  	 CC	O
the  	the  	 DT	O
effect  	effect  	 NN	O
of  	of  	 IN	O
rimonabant  	rimonabant  	 NN	B-NP
on  	on  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
events 	events 	 NNS	I-NP
,  	,  	 ,	O
developing  	developing  	 VBG	O
diabetes  	diabetes  	 NN	O
and  	and  	 CC	O
mortality 	mortality 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
lack  	lack  	 NN	O
of  	of  	 IN	O
data  	data  	 NNS	O
on  	on  	 IN	O
the  	the  	 DT	O
HRQoL  	HRQoL  	 JJ	B-NP
benefits  	benefits  	 NNS	I-NP
associated  	associated  	 VBN	O
with  	with  	 IN	O
rimonabant 	rimonabant 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
lack  	lack  	 NN	O
of  	of  	 IN	O
response  	response  	 NN	B-NP
hurdles  	hurdles  	 NNS	I-NP
applied  	applied  	 VBN	O
to  	to  	 TO	O
sibutramine  	sibutramine  	 VB	O
and  	and  	 CC	O
orlistat  	orlistat  	 JJ	B-NP
means  	means  	 NNS	I-NP
that  	that  	 IN	O
the  	the  	 DT	O
comparator  	comparator  	 JJ	B-NP
strategies  	strategies  	 NNS	I-NP
were  	were  	 VBD	O
not  	not  	 RB	O
considered  	considered  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
to  	to  	 TO	O
reflect  	reflect  	 VB	O
their  	their  	 PRP$	O
respective  	respective  	 JJ	O
product  	product  	 NN	B-NP
licenses  	licenses  	 NNS	I-NP
or  	or  	 CC	O
current  	current  	 JJ	O
NHS  	NHS  	 NNP	B-NP
use 	use 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
NICE  	NICE  	 NNP	O
guidance  	guidance  	 VBD	O
issued  	issued  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
result  	result  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
STA  	STA  	 NNP	B-NP
states  	states  	 NNS	I-NP
that  	that  	 IN	O
rimonabant  	rimonabant  	 NN	B-NP
is  	is  	 VBZ	O
recommended  	recommended  	 VBN	O
as  	as  	 IN	O
an  	an  	 DT	O
adjunct  	adjunct  	 NN	B-NP
to  	to  	 TO	O
diet  	diet  	 NN	O
and  	and  	 CC	O
exercise  	exercise  	 NN	O
for  	for  	 IN	O
adults  	adults  	 NNS	O
who  	who  	 WP	O
are  	are  	 VBP	O
obese  	obese  	 VBN	O
or  	or  	 CC	O
overweight  	overweight  	 NN	O
and  	and  	 CC	O
who  	who  	 WP	O
have  	have  	 VBP	O
had  	had  	 VBN	O
an  	an  	 DT	O
inadequate  	inadequate  	 JJ	O
response  	response  	 NN	O
to 	to 	 TO	O
,  	,  	 ,	O
are  	are  	 VBP	O
intolerant  	intolerant  	 VBN	O
of  	of  	 IN	O
or  	or  	 CC	O
are  	are  	 VBP	O
contraindicated  	contraindicated  	 VBN	O
to  	to  	 TO	O
orlistat  	orlistat  	 VB	O
and  	and  	 CC	O
sibutramine 	sibutramine 	 NN	B-NP
.  	.  	 .	O
